ArticleNature2021
Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 388 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
388citing papers in PubMed, 2 pooled it
34.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
388 citing papers in PubMed, 2 syntheses or guidelines pooled it, 560 citations in OpenAlex.
- From tumor microenvironment orchestrators to actionable targets: a systematic review of TAM-targeted therapies in triple-negative breast cancer.International journal of clinical oncology · 2026Pooled it
- The effect of disrupted sleep on macrophage polarization: a systematic review and meta-analysis of animal studies.BMC immunology · 2025Pooled it
- Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.Nature medicine · 2026Trial
- Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.Nature communications · 2024Trial
- Research on tissue-resident macrophages in the field of cancer research: a bibliometric analysis from 2004 to 2025.Cell adhesion & migration · 2026Review
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- Article
- Pan-cancer epigenetic landscape of human tumor-associated macrophages reveals crucial enhancers governing their heterogenous formation by Pol II pausing modulation.Journal of advanced research · 2026Article
- Alveolar Macrophages: Development, Respiratory Homeostasis, Signal Pathways, Diseases, and Therapeutic Opportunities.MedComm · 2026Review
- Multifocal ground-glass opacities in lung cancer: a narrative review of genomic evolution, immune ecology, and biology-informed clinical management.Journal of thoracic disease · 2026Review
- Widening the therapeutic window: How tumor irradiation harnesses dendritic cells to locally amplify CAR T cells in solid tumor.Molecular therapy. Oncology · 2026Article
- Reversing Macrophage Immunometabolic Dysfunction in Prolonged Infections Via a Glutaminolysis-Fueled Restoration-Based Hierarchically Selective Therapeutic System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity.The Journal of experimental medicine · 2026Article
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Breathing carcinogens: PMJournal of thoracic disease · 2026Review
- Lipid metabolic reprogramming of tumor-associated macrophages drives resistance to immune checkpoint blockade in lung cancer: a narrative review of mechanisms and therapeutic strategies.Translational lung cancer research · 2026Review
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma.Journal for immunotherapy of cancer · 2026Article
328 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
27 authors at 8 institutions in 4 countries.
María Casanova-AcebesDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. mcasanova@cnio.es.ORCID http://orcid.org/0000-0002-5790-1163
Erica Dalla *Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Andrew M Leader *Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jessica LeBerichel *Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jovan NikolicInstitut Curie, PSL Research University, INSERM U932, Paris, France.
Blanca M MoralesDepartment of Cancer Immunology, Genentech, South San Francisco, CA, USA.
Markus BrownDepartment of Cancer Immunology, Genentech, South San Francisco, CA, USA.
Christie ChangDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-7651-7220
Leanna TroncosoDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Steven T ChenDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ana Sastre-PeronaThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA.
Matthew D ParkDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alexandra TabachnikovaDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Maxime DhainautPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pauline HamonDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Barbara MaierDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Catherine M SawaiINSERM U1218 ACTION, University of Bordeaux, Bordeaux, France.
Esperanza Agulló-PascualMicroscopy CoRE, Dean's CoREs, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Markus SchoberThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA.
Brian D BrownPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3670-8778
Boris ReizisDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-1140-7853
Thomas MarronDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ephraim KenigsbergPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-4107-3295
Christine MoussionDepartment of Cancer Immunology, Genentech, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-1641-4094
Philippe BenarochInstitut Curie, PSL Research University, INSERM U932, Paris, France.
Julio A Aguirre-GhisoDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-6694-6507
Miriam MeradDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.ORCID http://orcid.org/0000-0002-4481-7827
Icahn School of Medicine at Mount Sinai · USInserm · FRNew York University · USAustrian Academy of Sciences · ATHospital La Paz Institute for Health Research · ESSpanish National Cancer Research Centre · ESTisch Hospital · USUniversité de Bordeaux · FR
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MViral Assays CoreU19AI128949 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2017 to 2026
$26.4MTRAINING PROGRAM IN CANCER THERAPYT32CA078207 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI James J Manfredi · 1999 to 2026
$11.6MFunctional Determinants of Metastatic DormancyR01CA109182 · NCI · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI AGUIRRE-GHISO, JULIO A. · 2005 to 2025
$8.3MDevelopment of a platform for spatial functional genomicsR01AT011326 · NCCIH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D · 2020 to 2024
$3.6MInvestigating Macrophage Molecular and Functional Diversity in Tumor ImmunityR01CA254104 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2021 to 2025
$3.4MDissecting the pathways driving progenitor to pro-tumor macrophage programmingR01CA257195 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown, MIRIAM MERAD · 2021 to 2026
$3.3M(7) Novel imaging devices for measurement and control of tumor microenvironmentsR01CA216248 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CADY, NATHANIEL CHARLES, CONDEELIS, JOHN S · 2017 to 2021
$2.9MEpigenetic and microenvironmental regulation of dormant disseminated cancerR01CA218024 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AGUIRRE-GHISO, JULIO A. · 2017 to 2021
$2.2MThe Immune Cell Atlas â A Robust Framework to Map the Entire Human Immune SystemR56AI137244 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENOIST, CHRISTOPHE O., HACOHEN, NIR · 2018 to 2018
$2.0MDissecting the aging of hematopoietic stem cells by genetic tracing in vivoR01AG049074 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI REIZIS, BORIS · 2015 to 2019
$1.7MUsing CRISPR/Cas9 Pro-code technology to dissect the migratory dendritic cell signatureF30CA243210 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHEN, STEVEN TIWEN · 2019 to 2022
$189kNCCIH NIH HHS R01 AT011326NCI NIH HHS F30 CA243210NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA109182NCI NIH HHS R01 CA216248NCI NIH HHS R01 CA218024NCI NIH HHS R01 CA254104NCI NIH HHS R01 CA257195NCI NIH HHS T32 CA078207NIAID NIH HHS R56 AI137244NIAID NIH HHS U19 AI128949NIA NIH HHS R01 AG049074
Abstract
Macrophages have a key role in shaping the tumour microenvironment (TME), tumour immunity and response to immunotherapy, which makes them an important target for cancer treatment
Indexed as
CarcinogenesisTumor MicroenvironmentAnimalsCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesEpithelial-Mesenchymal TransitionFemaleHumansLung NeoplasmsMacrophagesMaleMiceMice, Inbred C57BLNeoplasm InvasivenessT-Lymphocytes, Regulatory
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.